南京高科(600064.SH):孫公司9.8億元競得南京市一幅地塊
格隆匯 12 月 1日丨南京高科(600064.SH)公佈,2020年12月1日,公司控股子公司南京高科置業有限公司的全資子公司南京高科仙林湖置業有限公司參加了南京市國有建設用地使用權公開出讓的競買,並以9.8億元人民幣競得NO.2020G87號地塊。
南京市NO.2020G87地塊位於江寧區麒麟科創園中心區,東至滄波門南街,南至東麒路,西至光華路,北至智匯路。該地塊總用地面積50,881.89平方米,出讓面積50,881.89平方米,單獨出讓地下1,762.96平方米,綜合容積率3.0,建築密度≤50%,規劃用地性質為商住混合用地、商辦混合用地,掛牌出讓起始價為9.8億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.